Akorn, Inc. (NASDAQ:AKRX) Director Brian Tambi sold 15,100 shares of the stock in a transaction on Tuesday, November 21st. The shares were sold at an average price of $33.35, for a total value of $503,585.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Shares of Akorn, Inc. (NASDAQ AKRX) opened at $32.37 on Friday. Akorn, Inc. has a 52 week low of $17.61 and a 52 week high of $34.00. The company has a quick ratio of 3.17, a current ratio of 4.16 and a debt-to-equity ratio of 0.92. The firm has a market capitalization of $4,048.53, a price-to-earnings ratio of 20.11, a price-to-earnings-growth ratio of 1.93 and a beta of 1.33.

COPYRIGHT VIOLATION NOTICE: This report was posted by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The original version of this report can be read at https://www.watchlistnews.com/brian-tambi-sells-15100-shares-of-akorn-inc-akrx-stock/1723748.html.

Several analysts have recently issued reports on the company. Royal Bank Of Canada reiterated a “sector perform” rating and issued a $34.00 price objective on shares of Akorn in a research note on Sunday, August 20th. Piper Jaffray Companies set a $34.00 price objective on Akorn and gave the company a “hold” rating in a research note on Sunday, October 22nd. TheStreet cut Akorn from a “b-” rating to a “c” rating in a research note on Tuesday, August 1st. BidaskClub cut Akorn from a “hold” rating to a “sell” rating in a research note on Tuesday, August 1st. Finally, Jefferies Group LLC set a $34.00 price target on Akorn and gave the company a “hold” rating in a research note on Sunday, October 29th. Three investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and one has issued a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $29.38.

A number of institutional investors have recently bought and sold shares of the business. California Public Employees Retirement System raised its stake in Akorn by 1.0% in the third quarter. California Public Employees Retirement System now owns 271,100 shares of the company’s stock valued at $8,998,000 after buying an additional 2,600 shares in the last quarter. Janus Henderson Group PLC raised its stake in Akorn by 29.8% in the third quarter. Janus Henderson Group PLC now owns 38,555 shares of the company’s stock valued at $1,280,000 after buying an additional 8,856 shares in the last quarter. Cornerstone Capital Management Holdings LLC. raised its stake in Akorn by 1,277.6% in the third quarter. Cornerstone Capital Management Holdings LLC. now owns 331,214 shares of the company’s stock valued at $10,992,000 after buying an additional 307,171 shares in the last quarter. Allianz Asset Management GmbH raised its stake in Akorn by 3.7% in the third quarter. Allianz Asset Management GmbH now owns 1,502,253 shares of the company’s stock valued at $49,860,000 after buying an additional 53,588 shares in the last quarter. Finally, Alpine Associates Management Inc. grew its holdings in shares of Akorn by 395.7% during the third quarter. Alpine Associates Management Inc. now owns 1,189,216 shares of the company’s stock worth $39,469,000 after purchasing an additional 949,316 shares during the last quarter. Institutional investors own 74.66% of the company’s stock.

About Akorn

Akorn Inc (Akorn), together with its subsidiaries, is a specialty generic pharmaceutical company that develops, manufactures and markets generic and branded prescription pharmaceuticals, as well as private-label over-the-counter (OTC) consumer health products and animal health pharmaceuticals. The Company operates through two segments: Prescription Pharmaceuticals and the Consumer Health.

Receive News & Ratings for Akorn Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akorn Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.